Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – In hemodynamically stable preterm infants, there seems to be minimal clinical benefit to giving a single dose of furosemide right before packed red…
NEW YORK (Reuters Health) – Nearly 1 in 5 cancer patients treated with cisplatin-based chemotherapy have a thromboembolic event within a month of ending treatment, according to a…
NEW YORK (Reuters Health) – A combination of drugs designed to prevent pain, distress and physiologic instability in premature infants being intubated works better than premedication with morphine,…
NEW YORK (Reuters Health) – For patients with Alzheimer’s disease, prophylactic treatment with divalproex sodium does not delay the emergence of agitation or psychosis, or slow the progression…
Anthony Geraci, MD, Founder and President, neurOasis, provides an overview of the various treatments for migraine, including a class of medication called triptans and a new drug technology…
Anthony Geraci, MD, Founder and President, neurOasis, discusses the prevalence and hallmarks of migraines and what doctors and patients need to know when diagnosing the condition. A key…
NEW YORK (Reuters Health) – Results of two phase II trials investigating the addition of bortezomib to combination treatments of follicular lymphoma suggest that the strategy is feasible…
NEW YORK (Reuters Health) – Cardiac resynchronization therapy not only reduces the risk of a first heart failure event but also recurring events, according to an analysis of…
NEW YORK (Reuters Health) – Among children between 24 and 59 months of age, vaccination with trivalent inactivated influenza vaccine (TIV) is not associated with any serious adverse…
NEW YORK (Reuters Health) – Despite changes in the flora responsible for microbial keratitis, second-generation fluoroquinolone monotherapy remains the empirical treatment of choice, researchers from the UK report…
